Husch Blackwell litigators successfully defended Virtus Pharmaceuticals against a competitor’s claim that Virtus unfairly marketed one of its generic drugs. After opening statements at the U.S. International Trade Commission (ITC), the judge told the competitor that Virtus’ prehearing submissions were so persuasive that he was unlikely to rule in the competitor’s favor. The competitor withdrew its complaint, allowing patients continued access to Virtus’ lower-priced drug.